The short version of GHRH 类似物 fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic 44-residue GHRH analog | Sequence matches human GHRH(1-44); differs only at the N-terminus |
| Nominal molecular mass | Approximately 5,136 Da (free base) | Small variation arises from counterion and salt form |
| Appearance | White to off-white lyophilized powder | Supplied in single-use vials intended for reconstitution |
| Solubility class | Freely soluble in water | Practically insoluble in nonpolar organic solvents |
| Typical storage | 2 to 8 degrees Celsius, protected from light | Reconstituted material is handled according to label instructions |
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
tesamorelin 是一种人工合成的四十四肽，序列与内源性生长激素释放激素（GHRH）的 1-44 片段一致，区别在于 N 端加接了一个反式-3-己烯酰基。该修饰抑制二肽基肽酶 IV 的快速切割，从而延长分子在循环中的存留时间。作为肽类分子，它难以经胃肠道吸收，文献中讨论的均是注射途径。分类上通常把它归为 GHRH 类似物，以区别于生长激素本身。
作用位置在垂体前叶。tesamorelin 与 GHRH 受体结合后激活腺苷酸环化酶，升高细胞内 cAMP，再经蛋白激酶 A 通路促进生长激素的合成与释放。由于它作用于内源调控节点，生长激素仍以脉冲方式分泌，而不是被持续抬升到固定水平。生长激素随后在肝脏等组织诱导胰岛素样生长因子 1 产生，构成完整的生长激素轴响应。
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
Physicochemical behavior is dominated by the peptide backbone. The molecule is hydrophilic and carries a net positive charge near neutral pH, owing to several arginine and lysine residues. In solution it adopts a largely unstructured conformation, and aggregation is a known concern for peptide products of this size. Oxidation of methionine and deamidation of asparagine or glutamine residues are the principal chemical degradation routes. These liabilities shape how the material is formulated, handled, and analyzed, and they explain why lyophilized presentations are common in research settings.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, built from 44 amino acids. Its sequence follows the natural human GHRH(1-44) backbone, with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification blocks recognition by dipeptidyl peptidase IV, the enzyme that rapidly truncates the native hormone in circulation. The result is a molecule with a substantially longer plasma residence time than unmodified GHRH, which makes it practical for clinical and laboratory study.
Active hexose correlated compound (AHCC) is an alpha-glucan rich nutritional supplement produced from shiitake (Lentinula edodes). The product is a subject of research as a potential anti-cancer agent. AHCC is a popular alternative medicine in Japan. AHCC is a registered trademark of and manufactured by Amino Up Co., Ltd. in Sapporo City, Hokkaido, Japan. AHCC was developed by Amino Up Co., LTD. and Toshihiko Okamoto (School of Pharmaceutical Sciences, University of Tokyo) in 1989. Polysaccharides form a large part of the composition of AHCC. These include beta-glucan (β-glucan) and partially acylated α-glucan. Partially acylated α-glucan, produced by the patented long term culturing process, is unique to AHCC. Approximately 20% of the make up of AHCC is α-glucans. Glucans are saccharides, of which some are known to have immune stimulating effects.
Thorium is a chemical element; it has symbol Th and atomic number 90. Thorium is a weakly radioactive light silver metal which tarnishes olive grey when it is exposed to air, forming thorium dioxide; it is moderately soft, malleable, and has a high melting point. Thorium is an electropositive actinide whose chemistry is dominated by the +4 oxidation state; it is quite reactive and can ignite in air when finely divided. All known thorium isotopes are unstable. The most stable isotope, 232Th, has a half-life of 14.0 billion years, or about the age of the universe; it decays very slowly via alpha decay, starting a decay chain named the thorium series that ends at stable 208Pb. On Earth, thorium and uranium are the only elements with no stable or nearly-stable isotopes that still occur naturally in large quantities as primordial elements. Thorium is estimated to be over three times as abundant as uranium in the Earth's crust, and is chiefly refined from monazite sands as a by-product of extracting rare-earth elements. Thorium was discovered in 1828 by the Swedish chemist Jöns Jacob Berzelius during his analysis of a new mineral found by Morten Thrane Esmark in Norway on Løvøya island near Brevik in the Langesund fjord. He named it after Thor, the Norse god of thunder and war. Its first applications were developed in the late 19th century. Thorium's radioactivity was widely acknowledged during the first decades of the 20th century. In the second half of the 20th century, thorium was replaced in many uses due to concerns about its radioactive properties.
Hannibal had a history of the Punic Wars produced, and ordered it to be kept in the temple of Juno Lacinia in Crotone so that the Romans could not falsify the history of the war. Plutarch drew from that source. In the summer of 204 BCE the Romans arrived in Calabria and enslaved the Bruttians to punish their rebellion. Vast estates were requisitioned and assigned to members of the Roman aristocracy. During the Second Punic War (218–201 BCE) the Bruttii allied with Hannibal, who sent Hanno, one of his commanders, to Calabria. Hanno twice marched toward Capua (in Campania) with Bruttian soldiers to take them to Hannibal's headquarters there, but he was twice defeated. When his campaign in Italy came to an end, Hannibal took refuge in Calabria, whose steep mountains provided protection against the Roman legions. He set up his headquarters in Kroton and stayed there for four years until he was recalled to Carthage. The Romans fought a battle with him near Kroton, but its details are not recorded. Many Calabrian cities surrendered to the Romans and Calabria was put under a military commander.
== Weapons == Someone hit by a shotgun will not fly backwards like it is often portrayed in movies, and the same is true for other handheld weapons. The momentum of the bullet is no higher than the recoil transmitted to the shooter, which is too little to cause any significant motion. Land mines explode immediately when stepped on. They are not armed when stepped on and then triggered by stepping off, as depicted in fictional portrayals where disarming the mine is a source of narrative.
== Botanical usage == In botany, the term "integument" may be used as it is in zoology, referring to the covering of an organ. When the context indicates nothing to the contrary, the word commonly refers to an envelope covering the nucellus of the ovule. The integument may consist of one layer (unitegmic) or two layers (bitegmic), each of which consisting of two or more layers of cells. The integument is perforated by a pore, the micropyle, through which the pollen tube can enter. It may develop into the testa, or seed coat.
Sources: en.wikipedia.org
=== Synthesis === Early and seemingly inefficient syntheses of synephrine were discussed by Priestley and Moness, writing in 1940. These chemists optimized a route beginning with the O-benzoylation of p-hydroxy-phenacyl chloride, followed by reaction of the resulting O-protected chloride with N-methyl-benzylamine to give an amino-ketone. This intermediate was then hydrolyzed with HCl/alcohol to the p-hydroxy-aminoketone, and the product then reduced catalytically to give (racemic) synephrine. A later synthesis, due to Bergmann and Sulzbacher, began with the O-benzylation of p-hydroxy-benzaldehyde, followed by a Reformatskii reaction of the protected aldehyde with ethyl bromoacetate/Zn to give the expected β-hydroxy ester. This intermediate was converted to the corresponding acylhydrazide with hydrazine, then the acylhydrazide reacted with HNO2, ultimately yielding the p-benzyloxy-phenyloxazolidone. This was N-methylated using dimethyl sulfate, then hydrolyzed and O-debenzylated by heating with HCl, to give racemic synephrine.
=== Temple of the Theologic Virtues === On December 17, 1804, the Grand Lodge of Pennsylvania chartered the Temple of the Theologic Virtues, No. 103, (French: Le Temple des Vertus Théogales) at Havana. Joseph Cerneau, who had recently arrived from Saint-Domingue, was appointed its first Master. The Scottish Rite in these days only held 25 degrees, and Cerneau had achieved the 25th Degree that year. Cerneau's associates were Pierre Courroy and Pierre Bauschey. The original core of this Lodge were Frenchmen, who brought with them new ideas of the recent French Revolution. Cerneau was deported from Cuba in 1806, and wound up in the United States, where he established the Grand Consistory and the Cerneau Rite. The Temple of the Theologic Virtues remained intact, however, after his departure. On November 18, 1805, Reunion de Coeurs was added to the roster of French speaking Lodges seeking refuge from the Haitian Revolution, and reformed in Santiago de Cuba. In 1806, Concorde and Peseverance also established Lodges in Santiago de Cuba, where they adopted Spanish names. In Havana, the streets of Calle Amistad, Calle Concordia, and Calle Virtudes took their names from the Lodges that operated there. With the Napoleonic invasion of Spain in 1808, anti-French sentiment grew in Cuba. The French speaking Lodges began leaving the island with the refugees who had brought them.
== History == Faroese physician Niels Finsen is believed to be the father of modern light therapy. He used red light to treat smallpox lesions. He received the Nobel Prize in Physiology or Medicine in 1903. Scientific evidence for some of his treatments is lacking, and later eradication of smallpox and development of antibiotics for tuberculosis rendered light therapy obsolete for these diseases. Hungarian physician and surgeon Endre Mester (1903–1984) is credited with the discovery of the biological effects of low power lasers, which occurred a few years after the 1960 invention of the ruby laser and the 1961 invention of the helium–neon (HeNe) laser. Mester accidentally discovered that low-level ruby laser light could regrow hair during an attempt to replicate an experiment that showed that such lasers could reduce tumors in mice. The laser he was using was faulty and was not as powerful as believed. It failed to affect the tumors, but in places where the mice had been shaved in order to do the experiments, the hair grew back more quickly on the treated mice than on those among the control group. He published those results in 1967. Mester went on to show that low level HeNe light could accelerate wound healing in mice. By the 1970s, he was applying low level laser light to treat people with skin ulcers. In 1974, he founded the Laser Research Center at the Semmelweis Medical University in Budapest, and continued working there for the remainder of his life. His sons carried on his work and brought it to the United States.
=== Broken specimens === Broken specimens are reattached to the herbaria sheet using thinly cut strips of archival pre-gummed linen tape. Detached materials such as seeds or leaves are placed in an acid-free card fragment packet, which is secured onto the sheet with the original specimen.
Sources: en.wikipedia.org
It is a synthetic peptide built from 44 amino acids arranged in the same order as human growth hormone-releasing hormone. A short fatty-acid chain, described as a trans-3-hexenoyl group, is attached to the first amino acid. The finished molecule is formulated as a sterile powder that is dissolved before use.
No. It is a releasing-factor analog that signals the pituitary gland to secrete growth hormone, whereas recombinant growth hormone is the hormone itself administered directly. The two are chemically distinct and act at different points in the same endocrine pathway. This distinction is often lost in informal discussion.
Native growth hormone-releasing hormone is broken down within minutes by dipeptidyl peptidase-4 in the bloodstream. Adding the hexenoyl group at the N-terminus shields the peptide from that enzyme. The modification does not change the receptor it targets, only how long the peptide survives in circulation.
It is a synthetic peptide analog of human growth hormone-releasing hormone. It is used clinically to reduce excess visceral abdominal fat in adults with HIV-associated lipodystrophy. It works by stimulating pituitary growth hormone release.